GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (MEX:AGIO) » Definitions » Investments And Advances

Agios Pharmaceuticals (MEX:AGIO) Investments And Advances : MXN10,868.5 Mil (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Agios Pharmaceuticals Investments And Advances?

Agios Pharmaceuticals's Investments And Advances for the quarter that ended in Mar. 2025 was MXN10,868.5 Mil.

Agios Pharmaceuticals's quarterly Investments And Advances increased from Sep. 2024 (MXN12,914.7 Mil) to Dec. 2024 (MXN13,312.6 Mil) but then declined from Dec. 2024 (MXN13,312.6 Mil) to Mar. 2025 (MXN10,868.5 Mil).

Agios Pharmaceuticals's annual Investments And Advances declined from Dec. 2022 (MXN6,119.3 Mil) to Dec. 2023 (MXN499.6 Mil) but then increased from Dec. 2023 (MXN499.6 Mil) to Dec. 2024 (MXN13,312.6 Mil).


Agios Pharmaceuticals Investments And Advances Historical Data

The historical data trend for Agios Pharmaceuticals's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Investments And Advances Chart

Agios Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,941.62 5,464.42 6,119.29 499.64 13,312.63

Agios Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,930.16 1,381.41 12,914.65 13,312.63 10,868.48

Agios Pharmaceuticals Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Agios Pharmaceuticals Business Description

Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.